Are you Dr. Omelchenko?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
750 Brunswick Ave
Trenton, NJ 08638Phone+1 609-394-6031
Publications & Presentations
PubMed
- 3 citationsA Phase I/II Investigation of Safety and Efficacy of Nivolumab and-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.Erlinda M Gordon, Nicole L Angel, Nadezhda Omelchenko, Victoria S Chua-Alcala, Ania Moradkhani
Anticancer Research. 2023-05-01 - 1 citationsPhase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast.Howard W Bruckner, Sant P Chawla, Nadezhda Omelchenko, Don A Brigham, Erlinda M Gordon
Frontiers in Molecular Medicine. 2023-01-01 - 3 citationsActivity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).Sant P Chawla, Walter Andree Tellez, Hripsime Chomoyan, Chrysler Valencia, Amir Ahari
Frontiers in Oncology. 2023-01-01
